Is Cochlear Limited a buy at this share price?

Cochlear Limited (ASX:COH) shares have dropped as much as 4% today. Does this now make it a buy?

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Despite there being no news out of the company today, the shares of Cochlear Limited (ASX: COH) have drifted lower by as much as 4% to $129.62.

With the shares of the implantable hearing solutions specialist now down by almost 8% this month, is it time to invest in the company?

Although they have dropped down a fair bit, I would still suggest investors hold off investing for now. At 35x estimated FY 2017 earnings I'd prefer to see them drop further before making an investment.

In FY 2016 Cochlear delivered a 23% increase in revenue to $1.2 billion and a 30% increase in net profit after tax to $189 million. This impressive result has no doubt played a major role in driving its share price higher by as much as 36% year to date.

But for the year ahead management has only forecast net profit growth in the region of 10% to 20% on FY 2016's result. At 35x forward earnings the valuation is starting to look a little toppy in my eyes.

Whilst management does have a habit of under-promising and over-delivering, I would suggest at least waiting until its half year results to see how FY 2017 is panning out.

When shares trade on high multiples they run the risk of making steep declines should earnings growth fail to impress the market.

A prime example would be Healthscope Ltd (ASX: HSO). Its share price has tumbled by a massive 23% since it advised last week that its hospitals were having a weak first quarter.

Prior to the announcement Healthscope's shares were trading at around 27x full year earnings. Following the decline they are now changing hands at just 20x earnings.

Cochlear is undoubtedly a fantastic company, but at the current price I just cannot justify starting an investment in it. Instead investors might want to look at the more reasonably priced ResMed Inc. (CHESS) (ASX: RMD).

Not only are its shares changing hands at just 20x estimated FY 2017 earnings, but I believe it has solid long-term growth prospects that make this a more than fair price to pay.

Motley Fool contributor James Mickleboro has no position in any stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »